Holen Sie sich die Stockscreener-App
40.09
2.85%
1.11
Vorhandelsmarkt:
39.85
-0.24
-0.60%
Schlusskurs vom Vortag:
$38.98
Offen:
$39.05
24-Stunden-Volumen:
1.14M
Relative Volume:
1.80
Marktkapitalisierung:
$1.91B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.97M
KGV:
-16.57
EPS:
-2.4189
Netto-Cashflow:
$-81.88M
1W Leistung:
+34.21%
1M Leistung:
+23.54%
6M Leistung:
+44.47%
1J Leistung:
+281.81%
1-Tages-Spanne:
$37.84
$42.08
1-Wochen-Bereich:
$29.20
$42.08
52-Wochen-Spanne:
$9.43
$45.85
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
40.09 | 1.86B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-12-04 | Eingeleitet | Goldman | Sell |
| 2025-11-04 | Eingeleitet | TD Cowen | Buy |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-08-15 | Fortgesetzt | Jefferies | Buy |
| 2025-08-05 | Eingeleitet | Mizuho | Outperform |
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences shares fall despite positive one-year trial results for Canvuparatide (MBX) - MSN
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy? - Yahoo Finance
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Health Care Roundup: Market Talk - Moomoo
MBX News | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) Share Price, MBX Stock News, MBX Share Price & Updates - Kalkine
Mbx Biosciences90% of Patients in Ole Rema - Moomoo
MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk - Moomoo
Street canvu MBX phase II HP data more than one way - BioWorld News
MBX: Once-weekly kanvuparatide maintained durable efficacy and safety at one year, supporting phase III plans - TradingView
MBX reports one-year data for hypoparathyroidism drug candidate - Investing.com UK
MBX updates trial data for hypoparathyroidism drug (MBX:NASDAQ) - Seeking Alpha
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly CanvuparatideSlideshow (NASDAQ:MBX) 2026-06-12 - Seeking Alpha
Transcript : MBX Biosciences, Inc.Special Call - marketscreener.com
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) - Yahoo Finance
MBX Biosciences reports positive one-year canvuparatide data - grafa.com
MBX Biosciences stock falls despite one-year drug trial data - Investing.com UK
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell - marketscreener.com
MBX reports one-year data for hypoparathyroidism drug candidate By Investing.com - Investing.com Canada
MBX: Once-weekly canvuparatide maintained efficacy and safety at one year in chronic HP patients - TradingView
MBX Biosciences (Nasdaq: MBX) touts one-year canvuparatide data, plans Phase 3 - Stock Titan
Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism - TradingView
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism - The Manila Times
Once-weekly PTH drug from MBX maintained calcium and kidney measures for a year - Stock Titan
Richard B. Bartram (MBX) plans sale of 9,167 shares after option exercise - Stock Titan
MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise - Stock Titan
MBX Biosciences (MBX) director granted 12,500 stock options at $30.91 strike - Stock Titan
MBX Biosciences, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Registration on NASDAQ - Minichart
MBX Biosciences Shareholders Approve Directors and Auditor - TipRanks
MBX Biosciences: In Danger Of Being Outpaced By RivalsRating Downgrade (NASDAQ:MBX) - Seeking Alpha
MB elects two Class II directors to three-year terms through 2029 - TradingView
MBX Biosciences (MBX) grants stock options to director Ora Pescovitz - Stock Titan
MBX Biosciences (MBX) director and 10% owner receives 12,500 stock options grant - Stock Titan
MBX Biosciences (MBX) director receives stock options for 12,500 shares - Stock Titan
MBX Biosciences (MBX) director receives grant of 12,500 stock options at $30.91 - Stock Titan
MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options - Stock Titan
MBX Biosciences (MBX) director awarded 12,500 stock options - Stock Titan
MBX Biosciences (NASDAQ: MBX) 2026 meeting backs directors and Ernst & Young - Stock Titan
Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors? - Sahm
MBX: Once-weekly PTH and monthly obesity therapies show strong promise for efficacy, tolerability, and market impact - TradingView
MBX Biosciences, Inc. partners with HypoPARAassoc to advance treatment for over 100,000 hypoparathyroidism patients in U.S. - Traders Union
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 - The Manila Times
MBX Biosciences to host webcast on Phase 2 trial results of once-weekly canvuparatide at ENDO 2026 - Pluang
Number of shareholders of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run - AOL.com
3 Overlooked Stocks Set to Soar in 2026 - AOL.com
MBX Biosciences, Inc. executives to update on endocrine and metabolic disorder treatment advancements in New York - Traders Union
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - GlobeNewswire
MBX Biosciences Inc Share News (MBX) - Investing.com India
MBX Biosciences Inc. (MBX) Q1 2026 Earnings: EPS Beat as Pre-Revenue Biotech Advances PipelineProfit Warning Alert - Newser
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):